Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study).
Cardiac Catheterization Laboratory of the Zena & Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, New York 10029, USA.
Annapoorna S
AS
Kini
Merwin
M
Richard
Javed
J
Suleman
Nohelia
N
Perez
Paul
P
Lee
Edward A
EA
Fisher
Mazullah
M
Kamran
Jonathan D
JD
Marmur
Samin K
SK
Sharma
D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000191:economics; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D006328:Cardiac Catheterization / Q000191:economics; D009202:Cardiomyopathies / Q000473:pathology*; D003131:Combined Modality Therapy; D003402:Creatine Kinase / Q000097:blood; D052279:Creatine Kinase, MB Form; D000077542:Eptifibatide; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000191:economics / Q000627:therapeutic use*; D015994:Incidence; D007527:Isoenzymes / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000628:therapy; D009336:Necrosis; D010455:Peptides / Q000191:economics / Q000627:therapeutic use*; D010865:Pilot Projects; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000191:economics / Q000627:therapeutic use; D011237:Predictive Value of Tests; D013318:Stroke Volume / Q000502:physiology; D000077466:Tirofiban; D016896:Treatment Outcome; D019210:Troponin I / Q000097:blood; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D007527:Isoenzymes; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D019210:Troponin I; D014443:Tyrosine; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab